Clinical Trial Update: A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of subcutaneously administered trastuzumab (Herceptin) in patients with HER2-positive early breast cancer was terminated, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-09-29